Phase II trial of combination chemotherapy consisting of pegylated liposomal doxorubicin and carboplatin in patients with recurrent ovarian cancer - Phase II trial of PLD-carboplatin in recurrent ovarian cancer patients

Keio University, School of Medicine0 个研究点目标入组 33 人开始时间: 2009年10月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients with severe complications or active infection. 2. Patients with prior diagnosis of malignancy are not eligible. Exceptions are: -non-melanoma skin cancer, and carcinoma in situ. -other malignancies curatively treated and > 5 years without evidence of recurrence. 3. Patients with massive pleural effusion and/or ascites. 4. Patients with massive pericardial fluid. 5. Patients with unstable angina or those who have had a myocardial infarction within the past 90 days. 6. Patients with brain metastasis who have symptoms or require administration of steroid or antihydropic. 7. Patients who have received prior bone marrow transplantation, or high-dose chemotherapy and hematopoietic stem cell transplantation. 8. Patients who have received prior chemotherapy consisting of pegylated liposomal doxorubicin. 9. Patients who have participated in other clinical trials. 10. Patients who have received prior chemotherapy consisting of doxorubicin. 11. Patients with history of hypersensitivity reactions to the components of pegylated liposomal doxorubicin. 12. Patients who are pregnant, lactating, and have pregnant possibility or intention. 13. Patients who are decided to be ineligible for this trial by the investigators.

发起方